Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, Octavia, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/11/22 | $50,000,000 | Venture |
Flagship Pioneering | undisclosed |
